Superior Cognition in the Oldest-Old; Novel MS Pathway; What Links Amyloid and Tau?

Superior global cognition in the oldest-old was associated with resistance to neurodegenerative pathologies, autopsy data showed. (Journal of Alzheimer’s Disease)

Brain network models showed that people with higher intelligence scores took more time to solve difficult problems, and that slower solvers had higher average functional connectivity. (Nature Communications)

The novel investigational anti-CD40L antibody frexalimab reduced disease activity in relapsing multiple sclerosis (MS) in a phase II study, Sanofi said, shedding light on new possible pathway to treat MS.

Ocrelizumab (Ocrevus) had better outcomes for people with relapsing remitting MS who had quit natalizumab (Tysabri) than fingolimod (Gilenya) or dimethyl fumarate (Tecfidera). (JAMA Neurology)

CMS reiterated its plan to cover Alzheimer’s drugs that are granted traditional FDA approval for patients enrolled in a registry.

Astrocyte reactivity may be an important upstream event linking amyloid-beta with initial tau pathology in preclinical Alzheimer’s disease. (Nature Medicine)

Biogen is revising its Parkinson’s disease clinical development program for BIIB122, a small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2) that’s being developed with Denali Therapeutics.

Children with drug-resistant epilepsy who had cranial epilepsy surgery or vagus nerve stimulation had a higher survival rate than those who received medical treatment only. (Lancet Child & Adolescent Health)

Acute food intake altered Alzheimer’s plasma biomarkers in adults who were obese but otherwise healthy. (Alzheimer’s & Dementia)

Open-label data suggested the Parkinson’s drug ropinirole (Requip) may have benefit in amyotrophic lateral sclerosis. (Cell Stem Cell)

A nerve regeneration paper was retracted over fabricated data. (Cell Reports)